Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | CART22-65s cells |
Trade Name | |
Synonyms | anti-CD22 CAR T cells CART22-65s|anti-CD22 CAR 4-1BB-TCRz CART22-65s |
Drug Descriptions |
CART22-65s cells consist of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets CD22, and linked to 4-1BB (CD137) co-stimulatory domain and CD3 zeta chain, which potentially leads to lysis of tumor cells expressing CD22 and antitumor activity (NCI Drug Dictionary; Blood (2022) 140 (Supplement 1): 2376-2377). |
DrugClasses | CD22 Immune Cell Therapy 15 |
CAS Registry Number | NA |
NCIT ID | C156251 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
CART22-65s cells | CART22-65s cells | 0 | 1 |
CART22-65s cells + Cyclophosphamide + Fludarabine | CART22-65s cells Cyclophosphamide Fludarabine | 0 | 0 |
CART22-65s cells + huCART19 | CART22-65s cells huCART19 | 0 | 2 |